Meristem Therapeutics
This article was originally published in Start Up
Executive Summary
France's Meristem Therapeutics, spun out of seed producer Groupe Limagrain, is using transgenic plants to produce commercial quantities of purified protein-based pharmaceuticals. It hopes that the success of its phase II product, lipase, will help convince an as-yet skeptical pharmaceutical industry of the value--both in terms of safety, cost and efficiency--of plant-derived therapeutics.